Surmodics Past Earnings Performance

Past criteria checks 0/6

Surmodics's earnings have been declining at an average annual rate of -35.1%, while the Medical Equipment industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 6.6% per year.

Key information

-35.1%

Earnings growth rate

-35.4%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate6.6%
Return on equity-9.7%
Net Margin-9.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Jun 06
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 30
Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

May 02
Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Sep 17
We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Jun 26
News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Jun 22
An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

May 14
Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Apr 17
Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03
Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Jan 08
Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Surmodics gets additional $125M in credit facility

Oct 17

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Jul 27

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Jul 22
Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 03
Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Feb 04
Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Dec 24
Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Revenue & Expenses Breakdown

How Surmodics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SRDX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24126-12530
30 Jun 24121-15547
31 Mar 24143145147
31 Dec 2313865143
30 Sep 23133-25247
30 Jun 23131-235351
31 Mar 23103-365351
31 Dec 22102-325163
30 Sep 22100-274751
30 Jun 2298-13420
31 Mar 2297-10370
31 Dec 211062340
30 Sep 2110543249
30 Jun 211042300
31 Mar 211077300
31 Dec 20951280
30 Sep 20951280
30 Jun 201038280
31 Mar 201017270
31 Dec 191006260
30 Sep 191008250
30 Jun 19922240
31 Mar 1990-2230
31 Dec 1887-2240
30 Sep 1881-4230
30 Jun 1878-2220
31 Mar 18741220
31 Dec 17720210
30 Sep 17734200
30 Jun 17716200
31 Mar 17739190
31 Dec 167310190
30 Sep 167110180
30 Jun 16719170
31 Mar 16679160
31 Dec 156411150
30 Sep 156212130
30 Jun 156013150
31 Mar 155913150
31 Dec 145812150
30 Sep 145712150
30 Jun 145613150
31 Mar 145613160
31 Dec 135614150

Quality Earnings: SRDX is currently unprofitable.

Growing Profit Margin: SRDX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SRDX is unprofitable, and losses have increased over the past 5 years at a rate of 35.1% per year.

Accelerating Growth: Unable to compare SRDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).


Return on Equity

High ROE: SRDX has a negative Return on Equity (-9.71%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies